Scripps Research Discovery Leads to Broad Potential Applications in CovX-Pfizer Deal

LA JOLLA, Calif.--(BUSINESS WIRE)--Dec 19, 2007 - A catalytic antibody discovery made at The Scripps Research Institute has formed the basis of the upcoming acquisition of biotechnology venture CovX by pharmaceutical giant Pfizer, Inc. "I am deeply...

Comments

• Find It

• Recently Written

  • test post
  • ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
  • Amgen Posts Medical Education and Foundation Grants and Donations as Part of the Company’s ‘Clearly Amgen’ Initiative
  • FTC’s Bureau of Competition Issues FY 2007 Summary of Pharmaceutical Company Settlement Agreements
  • Study Finds Strong Social Factor in Quitting Smoking
  • Data re-analysis shows drug finasteride reduces risk for most prostate cancers
  • Merck ends study of cholesterol drug
  • Idaho gets share of $58 million Vioxx settlement with Merck
  • Dose of java before morning cereal alters blood sugar response
  • Possible Case: Cellcept, Myfortic

• Categories

  • News

• Monthly Archives

  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007

• Blogroll

  • Attorney Daily » Drug Injury News
  • Dangerous Drug Lawyer
  • Drugs.com - Pharma News
  • FDA MedWatch
  • Health Canada RSS
  • Lawyers and Settlements :: Drugs/Medical
  • Medication News

• Admin

  • Register
  • Log in
  • XHTML

Copyright © 2008 Drug Injury News